Drug Profile


Alternative Names: Dendritic cell/recombinant prostate-specific antigen vaccine; Dendritophages®/rPSA vaccine; Eladem; Eladem-1™; Eladem-2; IDD-1; Prostate cancer vaccine - IDM Pharma

Latest Information Update: 20 Oct 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IDM Pharma
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 23 Aug 2005 Phase-II clinical trials in Prostate cancer in Europe (Parenteral)
  • 16 Aug 2005 IDM S.A. has merged with Epimmune to form IDM Pharma
  • 07 Apr 2005 Clinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top